• Home
• Reports and publications
• Public policies

Reports and publications - Public policies

Anti-Bribery and Corruption (ABAC) Programme

Anti-Bribery and Corruption Programme Handbook
The Anti-Bribery and Corruption (ABAC) Programme is part of GSK’s response to the threat and risk of bribery and corruption.  The programme includes the ABAC Handbook, which has been designed to assist internal and external parties understand corruption risk and identify people’s responsibilities to actively combat both real and perceived corruption.

• GSK Anti-Bribery and Corruption Handbook (PDF 1Mb)

Anti-Bribery and Corruption Programme Third Party Guidelines

Third Party Guidelines are provided to all third parties that GSK engages with in order to make them aware of our anti-bribery and corruption policies and what we expect from them as our business partners.

• GSK Anti-Bribery and Corruption Guidelines for Third Parties (PDF 367Kb)

GSK access and developing countries

• Clinical trials in the developing world (PDF 103Kb)
• Developing world vaccine production technology transfer (PDF 80Kb)
• IP and access to medicines in developing countries (PDF 89Kb)
• Pandemic preparedness and developing countries (PDF (57Kb)
• Technology transfer, capacity building and developing countries (PDF 113Kb)
• Working together for the health of mothers and children (PDF 661Kb)

GSK and research & development

• Cloning technologies and stem cell research (PDF 87Kb)
• Disclosure of clinical trial information (PDF 84Kb)
• The care, welfare and treatment of animals (PDF 100Kb)
• The role of transgenic animals in biomedical research (PDF 128Kb)
• Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines (PDF 86Kb)

GSK and intellectual property

• Anti-Counterfeiting Trade Agreement (ACTA) (PDF 88Kb)
• Compulsory licences (PDF 82Kb)
• Evergreening (PDF 102Kb)
• Gene patenting (PDF 74Kb)
• Proposals for a disclosure in patent applications (PDF 91Kb)
• Regulatory data protection (PDF 159Kb)

GSK and the environment

• Climate change (PDF 176Kb)
• Hazardous chemical management (PDF 68Kb)
• Genetically modified micro-organisms and Environment, Health and Safety (EHS) (PDF 80Kb)
• GSK and REACH (PDF 50Kb)
• GSK and the convention on biological diversity (PDF 98Kb)
• Nanomaterials (PDF 66Kb)
• Ozone depletion and metered-dose inhalers for asthma (PDF 73Kb)
• Pharmaceuticals in environment (PDF 69Kb)
• The impact of climate change on health (PDF 75Kb)
• Use of ozone depleting substances in ancillary plant and equipment (PDF 177Kb)

GSK and public health

• Counterfeiting of healthcare products (PDF 115Kb)
• Pharmacovigilance (PDF 93Kb)
• Paediatric medicines (PDF 137Kb)
• Pandemic preparedness (PDF 103Kb)
• The provision by the pharma industry of information to patients (PDF 106Kb)

GSK and competitiveness

• Competitiveness and investment criteria (PDF 76Kb)
• Key aspects of a sustainable healthcare system (PDF 128Kb)

GSK pricing, reimbursement and market access

• Health technology assessments (PDF (107Kb)
• Incremental innovation (PDF 77Kb)
• Pricing and reimbursement (PDF 93Kb)

GSK and other issues

• Adjuvants (PDF 352Kb)
• Marketing practices (PDF 79Kb)
• Product donations (PDF 2.6Mb)